CD274 and neoplasm: In patients with high PD‐L1 expression (Tumor Proportion Score/TPS ≥ 50%) and absence of targetable genetic alterations, checkpoint inhibitor monotherapy, using atezolizumab, cemiplimab, or pembrolizumab, is also approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) [9, 10, 11, 12, 13, 14, 15, 16].